According to Syndicate Market Research, the global Florbetapir Market hit about USD 185 Million in 2024. The Florbetapir Market industry is expected to reach around USD 198 Million in 2025 and a whopping USD 365 Million by 2034, growing at a steady compound annual growth rate (CAGR) of roughly 7% from 2026 to 2034. The report analyzes the Florbetapir Market's drivers, restraints, and the impact it has on demand during the forecast period. Furthermore, it will assist in navigating and exploring emerging market prospects.
Florbetapir, also known as florbetapir F 18 or by its brand name Amyvid, is a radioactive diagnostic agent used in positron emission tomography (PET) imaging to estimate the density of beta-amyloid neuritic plaques in the brains of adult patients being evaluated for Alzheimer's disease and other causes of cognitive impairment. As the first FDA-approved amyloid PET tracer, it binds selectively to amyloid aggregates, enabling non-invasive visualization of pathological protein deposits that are hallmarks of Alzheimer's disease pathology, thereby supporting earlier and more accurate differential diagnosis when combined with clinical evaluation.
The market is propelled by the escalating global prevalence of Alzheimer's disease amid aging populations, growing adoption of advanced PET imaging in neurology, and supportive regulatory approvals that expand clinical indications. Key growth drivers include rising demand for early-stage diagnostics and integration with emerging blood-based biomarkers, while restraints arise from the short half-life of fluorine-18 requiring on-site cyclotron production, high costs of PET procedures, and competition from alternative amyloid tracers. Emerging trends encompass label expansions for broader cognitive impairment assessment, development of combined amyloid-tau imaging protocols, and increasing accessibility in emerging markets through localized manufacturing partnerships.
Key Insights
Growth Drivers Rising Alzheimer's prevalence and demand for early diagnosis
The growing elderly population and increasing awareness of Alzheimer's as a progressive neurodegenerative disorder have significantly boosted the need for reliable amyloid imaging, with florbetapir F 18 enabling physicians to confirm or rule out amyloid pathology in ambiguous cases of mild cognitive impairment.
Integration of PET amyloid imaging into updated diagnostic guidelines by organizations such as the Alzheimer's Association and recent label expansions further accelerate procedural uptake, particularly in memory clinics and specialized neurology practices.
Restraints Short half-life and high procedural costs
The 110-minute half-life of fluorine-18 necessitates proximity to cyclotrons and rapid distribution logistics, limiting accessibility in rural or underdeveloped regions and constraining market penetration.
High costs associated with PET scans, radiotracer production, and specialized imaging equipment continue to restrict widespread adoption in cost-sensitive healthcare systems despite clinical benefits.
Opportunities Emerging markets and multimodal imaging innovations
Rapid aging demographics in Asia Pacific and Latin America, coupled with expanding healthcare infrastructure investments, present substantial growth potential for localized manufacturing and distribution networks.
Development of hybrid amyloid-tau PET protocols and AI-assisted image quantification opens avenues for premium pricing and broader integration into precision neurology diagnostics.
Challenges Competition from alternative tracers and reimbursement hurdles
Availability of competing amyloid tracers such as flutemetamol and florbetaben, along with emerging tau and inflammation markers, intensifies market competition and pressures pricing strategies for established players.
Variable reimbursement policies across regions and stringent regulatory requirements for radiopharmaceuticals create barriers to consistent revenue growth and market expansion.
| Report Attributes | Report Details |
|---|---|
| Report Name | Florbetapir Market |
| Market Size in 2024 | USD 185 Million |
| Market Size in 2025 | USD 198 Million |
| Market Forecast in 2034 | USD 365 Million |
| Growth Rate (2026-2034) | CAGR of 7% |
| Base Year | 2025 |
| Historical Year | 2020 - 2024 |
| Forecast Year | 2026 - 2034 |
| Number of Pages | 225 |
| Report Coverage | Revenue Forecast, Market Dynamics, Company Profile, Competitive Landscape, Recent Developments, Growth Factors, and Recent Trends |
| Key Companies Covered | Eli Lilly and Company, Avid Radiopharmaceuticals Inc., Siemens Healthineers AG, GE Healthcare, Cardinal Health Inc., and Others. |
| Segments Covered | By Type, By Application, By End-User, and By Region |
| Regions Covered | North America, Europe, Asia Pacific (APAC), Latin America, and The Middle East and Africa (MEA) |
| Customization Scope | Customization for Segments, Region, Country-level will be provided. Avail customized purchase options to meet your exact research needs. Request For Customization |
The Florbetapir Market is segmented by type, application, end-user, and region.
Based on Type Segment, The Florbetapir Market is divided into 30 mL Vial, 10 mL Vial, and others. The 30 mL Vial is the most dominant segment because it aligns with standard clinical dosing protocols for adult patients, offers optimal efficiency in high-volume PET centers, and minimizes waste while ensuring consistent radiochemical purity; this dominance drives market growth by facilitating seamless integration into routine diagnostic workflows and supporting large-scale hospital procurement. The 10 mL Vial ranks as the second most dominant, catering to pediatric or low-dose research applications where smaller volumes reduce radiation exposure and cost, thereby expanding utility in specialized research institutes and contributing to incremental volume growth.
Based on Application Segment, The Florbetapir Market is divided into Alzheimer's Disease Diagnosis, Research Applications, and others. Alzheimer's Disease Diagnosis is the most dominant segment, commanding the majority share as it represents the primary approved indication and addresses the urgent clinical need for definitive amyloid plaque visualization in cognitive impairment cases; this leadership propels overall market expansion through increased physician confidence and procedural standardization. Research Applications is the second most dominant segment, leveraging florbetapir in clinical trials for novel Alzheimer's therapies and longitudinal studies, which fosters innovation pipelines and sustains long-term demand stability.
Based on End-User Segment, The Florbetapir Market is divided into Diagnostic Imaging Centers, Hospitals, Research Institutes, and others. Diagnostic Imaging Centers dominate owing to their dedicated PET infrastructure, specialized technologist expertise, and ability to handle time-sensitive radiotracers efficiently, enabling higher throughput and better patient access that directly accelerates market revenue. Hospitals rank second most dominant, particularly tertiary care facilities with integrated neurology departments, where florbetapir supports multidisciplinary Alzheimer's evaluation and drives procedural growth through inpatient and outpatient referrals.
In June 2025, the U.S. FDA approved a label update for Amyvid (florbetapir F 18 injection), expanding its clinical utility for estimating amyloid plaque density in a broader range of patients with cognitive impairment and strengthening its position as a cornerstone diagnostic tool.
In late 2024, Eli Lilly expanded its radiopharmaceutical manufacturing network through strategic partnerships with cyclotron operators in Europe, improving supply chain reliability and reducing delivery times for florbetapir doses to key diagnostic centers.
Major industry players have initiated pilot programs integrating artificial intelligence-based image analysis with florbetapir PET scans, demonstrating improved diagnostic accuracy and paving the way for standardized reporting protocols across global neurology practices.
North America to dominate the global market
North America leads the global Florbetapir Market with the largest share, underpinned by the United States' early regulatory approvals, robust reimbursement frameworks under Medicare, and high concentration of specialized memory clinics and PET facilities; the U.S. remains the dominant country through extensive adoption in Alzheimer's research networks and strong pharmaceutical support from domestic manufacturers. Canada contributes steadily via public healthcare integration of amyloid imaging.
Europe maintains significant momentum, led by Germany, France, and the United Kingdom, where aging populations and national dementia strategies drive PET tracer utilization; favorable EMA guidelines and growing private imaging centers further bolster regional expansion despite varying reimbursement landscapes.
Asia Pacific represents the fastest-growing region, with Japan, China, and South Korea at the forefront due to rising Alzheimer's awareness, government investments in nuclear medicine infrastructure, and increasing clinical trials incorporating amyloid PET; India and Southeast Asian nations are emerging through localized production initiatives.
Latin America and the Middle East & Africa show promising but nascent growth, with Brazil and South Africa leading through urban diagnostic hubs and international collaborations that gradually improve access to advanced neuroimaging for neurodegenerative disease management.
Some of the significant players in the global Florbetapir Market include;
By Type
By Application
By End-User
By Region
Frequently Asked Questions
What is Florbetapir Market? The Florbetapir Market encompasses the global production, distribution, and clinical utilization of florbetapir F 18 injection, a radiopharmaceutical PET tracer primarily used for imaging amyloid plaques in Alzheimer's disease evaluation.
What are the principal factors expected to drive expansion in the Florbetapir Market between 2026 and 2034? Principal drivers include the growing global Alzheimer's disease burden, expanding PET imaging infrastructure, regulatory label expansions, and integration with emerging multimodal diagnostic approaches that enhance clinical decision-making.
What is the projected market size of the Florbetapir Market from 2026 to 2034? The market is projected to grow from approximately USD 198 Million in 2025 to USD 365 Million by 2034.
What overall growth rate (CAGR) is the Florbetapir Market predicted to achieve between 2026 and 2034? The market is predicted to achieve a CAGR of roughly 7% between 2026 and 2034, fueled by rising diagnostic demand and technological advancements in nuclear medicine.
Which geographic region is forecasted to be a leading contributor to the overall Florbetapir Market valuation? North America is forecasted to be the leading contributor, supported by advanced healthcare systems, favorable reimbursement, and high adoption of amyloid PET imaging in the United States.
Who are the top companies dominating and driving the Florbetapir Market forward? Top companies include Eli Lilly and Company, Avid Radiopharmaceuticals Inc., Siemens Healthineers AG, and GE Healthcare, which lead through innovation, manufacturing expansions, and strategic partnerships in radiopharmaceutical distribution.
What key information or findings can typically be expected from the global Florbetapir Market report? The report delivers detailed market sizing, CAGR projections, segmental and regional breakdowns, competitive landscape analysis, growth drivers, restraints, recent regulatory updates, and strategic recommendations for stakeholders.
What are the various stages in the value chain of the global Florbetapir Market industry? The value chain spans cyclotron production of fluorine-18, chemical synthesis and radiolabeling of florbetapir, quality control and purification, cold-chain distribution due to short half-life, administration at imaging centers, PET scan acquisition, and interpretation by nuclear medicine specialists.
How are current market trends and evolving consumer preferences influencing the Florbetapir Market? Trends toward early Alzheimer's detection, AI-enhanced image quantification, and patient preference for non-invasive diagnostics are increasing demand for reliable amyloid tracers while shifting focus toward accessible and cost-effective imaging solutions.
What regulatory changes or environmental factors are impacting the growth of the Florbetapir Market? Recent FDA label updates and EMA harmonization efforts are positively influencing growth, while radiation safety regulations and environmental concerns around cyclotron operations require ongoing compliance investments by manufacturers.
These players adopted different strategies so as to hold major market share in this market. Some of the major players in [keyword] industry includes. [players list]
Based on the [keyword] market analysis, North America is predicted to held the highest share in the [keyword] market during the forecast period.
The statistical data of the top market players of [keyword] industry can be obtained from the company profile section specified in the report. This section incorporates analysis of top player’s operating in the [keyword] industry as well as their last five-year revenue, segmental revenue, product offerings, key strategies adopted, and geographical revenue produced.
The study offers a decisive view on the [keyword] by segmenting the market based on [segment1], [segment2], and region.
The report gives a nitty-gritty assessment of the market by featuring data on various viewpoints that incorporate drivers, restraints, opportunities, and threats. This data can assist stakeholders in making suitable decisions before investing.
The sample for [keyword] market report can be received on-demand from the website as and when required.Direct call services or 24*7 chat support are provided to procure the sample report.
1.1 Research Methodology
The process of market research at Syndicate Market Research is an iterative in nature and usually follows following path. Information from secondary is used to build data models, further the results obtained from data models are validated from primary participants. Then cycle repeats where, according to inputs from primary participants, additional secondary research is done and new information is again incorporated into data model. The process continues till desired level of information is not generated.
To calculate the market size, the report considers the revenue generated from the sales of the market providers. The revenue generated from the sales of market is calculated through primary and secondary research. The key players operating in the market across the globe are identified through secondary research and a corresponding detailed analysis of the top vendors in the market is done. The market size calculation also includes clinical trial phase segmentation determined using secondary sources and verified through primary sources.
1.2 Secondary Research
The secondary research sources that are typically referred to include, but are not limited to:
The sources for secondary research includes but is not limited to: Factiva, Hoovers and Statista
1.3 Primary Research
We conduct primary interviews on an ongoing basis with industry participants and commentators in order to validate data and analysis. A typical research interview fulfills the following functions:
The participants who typically take part in such a process include, but are not limited to:
1.4 Models
Where no hard data is available, we use modeling and estimates in order to produce comprehensive data sets. A rigorous methodology is adopted in which the available hard data is cross referenced with the following data types to produce estimates:
Data is then cross checked by the expert panel.
1.4.1 Company Share Analysis Model
Company share analysis is used to derive the size of global market. As well as study of revenues of companies for last three to five years also provide the base for forecasting the market size and its growth rate. This model is built in following steps:
1.4.2 Revenue Based Modeling
Revenue based models can be built in two ways - Top-Down or Bottom-Up irrespective of industry. Market size estimated from company share analysis acts as a validation point for bottom-up approach where as it acts as starting point for top-down approach.
1.5 Research Limitations
Inflation is not a part of pricing in this report. Prices of the products and its derivatives vary in each region and hence similar revenue ratio does not follow for each individual region. The same price for each type has been taken into account while estimating and forecasting market revenue on a global basis. Regional average price has been considered while breaking down this market by end user in each region.
We focus on the quality and accuracy of the report
Our expert team will assist with all your research needs and customize the report
Get you queries resolved from our expert analysts before and after purchasing the report
Instant delivery in the form of a PDF/PPT/Word Doc to your email address, within 12 hours after receiving the full payment.
Analysts will provide deep insights about the reports
* We value your privacy and will never rent or sell your email address.
Comprehensive & Focused Market Reports Large Archive of Excellent Market and Industry Analysis Reports that Deliver Business Intelligence.
Safe & Secure Payment Solutions
Enabled by SSL, we provide you numerous safe payment options for
risk-free transactions.
Superior Customer Experience We serve our
customers through calls, emails and live chats for 365 days, 24x7.
Syndicate Market Research provides a range of marketing and business research solutions designed for our client’s specific needs based on our expert resources. Read More
We accept the following payment methods
